Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(9):1405–1411. doi: 10.1038/sj.bjc.6690536

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes

G M Taylor 1, D A Gokhale 1, D Crowther 2, P J Woll 2,1, M Harris 3, D Ryder 4, M Ayres 1, J A Radford 2
PMCID: PMC2363076  PMID: 10424743

Abstract

It has been suggested in a number of studies that susceptibility to adult Hodgkin's disease (HD) is influenced by the HLA class II region, and specifically by alleles at the HLA-DPB1 locus. Since HD is diagnostically complex, it is not clear whether different HLA-DPB1 alleles confer susceptibility to different HD subtypes. To clarify this we have extended a previous study to type DPB1 alleles in 147 adult HD patients from a single centre. We have analysed patients with nodular sclerosing (NS), mixed cellularity (MC) or lymphocyte predominant (LP) HD, and gender in relation to HLA-DPBI type, in comparison with 183 adult controls. The results confirmed previously reported associations of DPB1*0301 with HD susceptibility (relative risk (RR) = 1.42; 95% confidence interval (CI) 0.86–2.36) and DPB1*0201 with resistance to HD (RR = 0.49; CI 0.27–0.90). However, analysis by HD subtype and gender showed that *0301-associated susceptibility was confined to females with HD (RR = 2.46; CI 1.02–5.92), and *0201-associated resistance to females with NS-HD (RR = 0.28; CI 0.10–0.79). Susceptibility to NS-HD was also associated in females with *1001 (RR = 11.73; CI 1.32–104.36), and resistance with *1101 (RR = 0.08; CI 0.01–0.65). In contrast, susceptibility to LP-HD was associated in males with *2001 (RR = 32.14; CI 3.17–326.17), and to MC-HD with *3401 (RR = 16.78; CI 2.84–99.17). Comparison of DPB1-encoded polymorphic amino-acid frequencies in patients and controls showed that susceptibility to MC-HD was associated with Leucine at position 35 of DPB1 (RR = 8.85; CI 3.04–25.77), Alanine-55 (RR = 15.17; CI 2.00–115.20) and Valine-84 (RR = 15.94; CI 3.55–71.49). In contrast, Glutamic acid 69 was significantly associated with resistance to MC-HD (RR = 0.14; CI 0.03–0.60). Certain DPB1 alleles and individual DPβ1 polymorphic amino acid residues may thus affect susceptibility and resistance to specific HD subtypes. This may be through their influence on the binding of peptides derived from an HD-associated infectious agent, and the consequent effect on immune responses to the agent. © 1999 Cancer Research Campaign

Keywords: Hodgkin's disease, HLA-DPB1, HVR, susceptibility, resistance, polymorphic amino acid

Full Text

The Full Text of this article is available as a PDF (85.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander F. E., McKinney P. A., Williams J., Ricketts T. J., Cartwright R. A. Epidemiological evidence for the 'two-disease hypothesis' in Hodgkin's disease. Int J Epidemiol. 1991 Jun;20(2):354–361. doi: 10.1093/ije/20.2.354. [DOI] [PubMed] [Google Scholar]
  2. Alexander F. E., Ricketts T. J., McKinney P. A., Cartwright R. A. Community lifestyle characteristics and incidence of Hodgkin's disease in young people. Int J Cancer. 1991 Apr 22;48(1):10–14. doi: 10.1002/ijc.2910480103. [DOI] [PubMed] [Google Scholar]
  3. Bodmer J. G., Tonks S., Oza A. M., Lister T. A., Bodmer W. F. HLA-DP based resistance to Hodgkin's disease. Lancet. 1989 Jun 24;1(8652):1455–1456. doi: 10.1016/s0140-6736(89)90166-9. [DOI] [PubMed] [Google Scholar]
  4. Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993 Jul 1;364(6432):33–39. doi: 10.1038/364033a0. [DOI] [PubMed] [Google Scholar]
  5. Bugawan T. L., Begovich A. B., Erlich H. A. Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes. Immunogenetics. 1990;32(4):231–241. doi: 10.1007/BF00187094. [DOI] [PubMed] [Google Scholar]
  6. Fu X. T., Bono C. P., Woulfe S. L., Swearingen C., Summers N. L., Sinigaglia F., Sette A., Schwartz B. D., Karr R. W. Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med. 1995 Mar 1;181(3):915–926. doi: 10.1084/jem.181.3.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Germain R. N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 1994 Jan 28;76(2):287–299. doi: 10.1016/0092-8674(94)90336-0. [DOI] [PubMed] [Google Scholar]
  8. Glaser S. L., Jarrett R. F. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol. 1996 Sep;9(3):401–416. doi: 10.1016/s0950-3536(96)80018-7. [DOI] [PubMed] [Google Scholar]
  9. Gokhale D. A., Evans D. G., Crowther D., Woll P., Watson C. J., Dearden S. P., Fergusson W. D., Stevens R. F., Taylor G. M. Molecular genetic analysis of a family with a history of Hodgkin's disease and dyschondrosteosis. Leukemia. 1995 May;9(5):826–833. [PubMed] [Google Scholar]
  10. Gutensohn N., Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med. 1981 Jan 15;304(3):135–140. doi: 10.1056/NEJM198101153040302. [DOI] [PubMed] [Google Scholar]
  11. Gutensohn N., Cole P. Epidemiology of hodgkin's disease in the young. Int J Cancer. 1977 May 15;19(5):595–604. doi: 10.1002/ijc.2910190502. [DOI] [PubMed] [Google Scholar]
  12. Hammer J., Gallazzi F., Bono E., Karr R. W., Guenot J., Valsasnini P., Nagy Z. A., Sinigaglia F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med. 1995 May 1;181(5):1847–1855. doi: 10.1084/jem.181.5.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hammer J. New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol. 1995 Apr;7(2):263–269. doi: 10.1016/0952-7915(95)80013-1. [DOI] [PubMed] [Google Scholar]
  14. Jarrett R. F. Viruses and Hodgkin's disease. Leukemia. 1993 Aug;7 (Suppl 2):S78–S82. [PubMed] [Google Scholar]
  15. Khan G., Coates P. J., Gupta R. K., Kangro H. O., Slavin G. Presence of Epstein-Barr virus in Hodgkin's disease is not exclusive to Reed-Sternberg cells. Am J Pathol. 1992 Apr;140(4):757–762. [PMC free article] [PubMed] [Google Scholar]
  16. Klitz W., Aldrich C. L., Fildes N., Horning S. J., Begovich A. B. Localization of predisposition to Hodgkin disease in the HLA class II region. Am J Hum Genet. 1994 Mar;54(3):497–505. [PMC free article] [PubMed] [Google Scholar]
  17. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  18. Marsh S. G. Nomenclature for factors of the HLA system, update May/June 1997. WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens. 1997 Oct;50(4):419–420. doi: 10.1111/j.1399-0039.1997.tb02895.x. [DOI] [PubMed] [Google Scholar]
  19. Mauch P. M., Kalish L. A., Kadin M., Coleman C. N., Osteen R., Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993 Mar 15;71(6):2062–2071. doi: 10.1002/1097-0142(19930315)71:6<2062::aid-cncr2820710622>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  20. Nei M., Roychoudhury A. K. Sampling variances of heterozygosity and genetic distance. Genetics. 1974 Feb;76(2):379–390. doi: 10.1093/genetics/76.2.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oudejans J. J., Jiwa N. M., Meijer C. J. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander. J Pathol. 1997 Apr;181(4):353–356. doi: 10.1002/(SICI)1096-9896(199704)181:4<353::AID-PATH782>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  22. Oza A. M., Tonks S., Lim J., Fleetwood M. A., Lister T. A., Bodmer J. G. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. Cancer Res. 1994 Oct 1;54(19):5101–5105. [PubMed] [Google Scholar]
  23. Pan L. X., Diss T. C., Peng H. Z., Norton A. J., Isaacson P. G. Nodular lymphocyte predominance Hodgkin's disease: a monoclonal or polyclonal B-cell disorder? Blood. 1996 Mar 15;87(6):2428–2434. [PubMed] [Google Scholar]
  24. Pellegris G., Lombardo C., Cantoni A., Devizzi L., Balzarotti M. Study of the HLA-DP beta 1 locus by the polymerase chain reaction technique in patients with Hodgkin's disease. Tumori. 1993 Apr 30;79(2):133–136. doi: 10.1177/030089169307900211. [DOI] [PubMed] [Google Scholar]
  25. Potolicchio I., Mosconi G., Forni A., Nemery B., Seghizzi P., Sorrentino R. Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol. 1997 Oct;27(10):2741–2743. doi: 10.1002/eji.1830271039. [DOI] [PubMed] [Google Scholar]
  26. Radford J. A., Crowther D., Rohatiner A. Z., Ryder W. D., Gupta R. K., Oza A., Deakin D. P., Arnott S., Wilkinson P. M., James R. D. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol. 1995 Sep;13(9):2379–2385. doi: 10.1200/JCO.1995.13.9.2379. [DOI] [PubMed] [Google Scholar]
  27. Sheehe P. R. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health. 1966 Oct;56(10):1745–1750. doi: 10.2105/ajph.56.10.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Skare J. C., Grierson H. L., Sullivan J. L., Nussbaum R. L., Purtilo D. T., Sylla B. S., Lenoir G. M., Reilly D. S., White B. N., Milunsky A. Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Hum Genet. 1989 Jul;82(4):354–358. doi: 10.1007/BF00273997. [DOI] [PubMed] [Google Scholar]
  29. Taylor G. M., Gokhale D. A., Crowther D., Woll P., Harris M., Alexander F., Jarrett R., Cartwright R. A. Increased frequency of HLA-DPB1*0301 in Hodgkin's disease suggests that susceptibility is HVR-sequence and subtype-associated. Leukemia. 1996 May;10(5):854–859. [PubMed] [Google Scholar]
  30. Tonks S., Oza A. M., Lister T. A., Bodmer J. G. Association of HLA-DPB with Hodgkin's disease. Lancet. 1992 Oct 17;340(8825):968–969. doi: 10.1016/0140-6736(92)92850-f. [DOI] [PubMed] [Google Scholar]
  31. Vianna N. J., Greenwald P., Davies J. N. Nature of Hodgkin's disease agent. Lancet. 1971 Apr 10;1(7702):733–736. doi: 10.1016/s0140-6736(71)91995-7. [DOI] [PubMed] [Google Scholar]
  32. Vianna N. J. Is Hodgkin's disease infectious? Cancer Res. 1974 May;34(5):1149–1155. [PubMed] [Google Scholar]
  33. Weiss L. M., Movahed L. A., Warnke R. A., Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989 Feb 23;320(8):502–506. doi: 10.1056/NEJM198902233200806. [DOI] [PubMed] [Google Scholar]
  34. Wu T. C., Mann R. B., Charache P., Hayward S. D., Staal S., Lambe B. C., Ambinder R. F. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990 Nov 15;46(5):801–804. doi: 10.1002/ijc.2910460509. [DOI] [PubMed] [Google Scholar]
  35. Zerva L., Cizman B., Mehra N. K., Alahari S. K., Murali R., Zmijewski C. M., Kamoun M., Monos D. S. Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. J Exp Med. 1996 Mar 1;183(3):829–836. doi: 10.1084/jem.183.3.829. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES